Deans' stroke musings: Novartis aims to show strength with muscle wasting drug

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Friday, December 6, 2013

Novartis aims to show strength with muscle wasting drug

Demand your doctor see if you need something like this if you are immobile. Who the hell is going to research this for stroke other than a great stroke association?
http://uk.reuters.com/article/2013/12/06/us-novartis-musclewasting-drug-idUKBRE9B50KF20131206

It is betting that the drug, known as bimagrumab or BYM338 and developed with German biotech company MorphoSys, might help combat muscle loss associated with conditions like cancer and chronic lung disease that affect millions of people.
It could even be beneficial for patients recovering from injury or an operation, and the drugmaker is currently conducting a Phase II trial for hip fracture recovery.
Novartis is not the only pharmaceutical firm working on muscle-building treatments. But it is heading the field in sIBM with BYM338, which was granted breakthrough therapy status from U.S. health regulators in August and is entering late-stage trials. It expects to file for approval in 2016.
Eli Lily is coming up close behind with two mid-stage studies for its drug LY2495655 as a treatment for muscle weakness and muscular atrophy.
Meanwhile, Regeneron and Sanofi have a drug in early stage development as a treatment for sarcopenia, the muscle loss associated with aging.

More at link.